A phase III randomised controlled trial of erlotinib vs gefitinib in advanced non-small cell lung cancer with EGFR mutations

Details 詳細情報について

• CRID

  1362544419253118080

• DOI

  10.1038/bjc.2016.456

• ISSN

  15321827

  00070920

• Web Site

  http://www.nature.com/articles/bjc2016456.pdf

  http://www.nature.com/articles/bjc2016456

• Data Source

  • Crossref